Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma.
Adult
Aged
Aged, 80 and over
Bone Neoplasms
/ secondary
Carcinoma, Renal Cell
/ mortality
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Kidney Neoplasms
/ mortality
Male
Margins of Excision
Middle Aged
Multivariate Analysis
Necrosis
Neoplasm Recurrence, Local
/ epidemiology
Neoplasm Staging
Proportional Hazards Models
Risk Factors
Young Adult
Chromophobe renal cell carcinoma
Follow-up
Nephrectomy
Renal cell carcinoma
Survival
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
05
01
2021
accepted:
24
03
2021
pubmed:
15
4
2021
medline:
19
2
2022
entrez:
14
4
2021
Statut:
ppublish
Résumé
Currently there are no specific guidelines for the post-operative follow-up of chromophobe renal cell carcinoma (chRCC). We aimed to evaluate the pattern, location and timing of recurrence after surgery for non-metastatic chRCC and establish predictors of recurrence and cancer-specific death. Retrospective analysis of consecutive surgically treated non-metastatic chRCC cases from the Royal Free London NHS Foundation Trust (UK, 2015-2019) and the international collaborative database RECUR (15 institutes, 2006-2011). Kaplan-Meier curves were plotted. The association between variables of interest and outcomes were analysed using univariate and multivariate Cox proportional hazards regression models with shared frailty for data source. 295 patients were identified. Median follow-up was 58 months. The five and ten-year recurrence-free survival rates were 94.3% and 89.2%. Seventeen patients (5.7%) developed recurrent disease, 13 (76.5%) with distant metastases. 54% of metastatic disease diagnoses involved a single organ, most commonly the bone. Early recurrence (< 24 months) was observed in 8 cases, all staged ≥ pT2b. 30 deaths occurred, of which 11 were attributed to chRCC. Sarcomatoid differentiation was rare (n = 4) but associated with recurrence and cancer-specific death on univariate analysis. On multivariate analysis, UICC/AJCC T-stage ≥ pT2b, presence of coagulative necrosis, and positive surgical margins were predictors of recurrence and cancer-specific death. Recurrence and death after surgically resected chRCC are rare. For completely excised lesions ≤ pT2a without coagulative necrosis or sarcomatoid features, prognosis is excellent. These patients should be reassured and follow-up intensity curtailed.
Identifiants
pubmed: 33851271
doi: 10.1007/s00345-021-03683-9
pii: 10.1007/s00345-021-03683-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3823-3831Subventions
Organisme : Medical Research Council
ID : MR/S00209X/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
pubmed: 30207593
pmcid: 30207593
Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 70(1):93–105. https://doi.org/10.1016/j.eururo.2016.02.029
doi: 10.1016/j.eururo.2016.02.029
pubmed: 26935559
Davis Caleb F, Ricketts CJ, Wang M, Yang L, Cherniack Andrew D, Shen H, Buhay C, Kang H, Kim Sang C, Fahey Catherine C, Hacker Kathryn E, Bhanot G, Gordenin Dmitry A, Chu A, Gunaratne Preethi H, Biehl M, Seth S, Kaipparettu Benny A, Bristow Christopher A, Donehower Lawrence A, Wallen Eric M, Smith Angela B, Tickoo Satish K, Tamboli P, Reuter V, Schmidt Laura S, Hsieh James J, Choueiri Toni K, Hakimi AA, Creighton Chad J, Davis Caleb F, Morgan M, Gunaratne Preethi H, Donehower Lawrence A, Kaipparettu Benny A, Wheeler David A, Gibbs Richard A, Signoretti S, Cherniack Andrew D, Robertson AG, Chu A, Choueiri Toni K, Henske Elizabeth P, Kwiatkowski David J, Reuter V, Hsieh James J, Hakimi AA, Tickoo Satish K, Ricketts C, Linehan WM, Schmidt Laura S, Gordenin Dmitry A, Bhanot G, Seiler M, Tamboli P, Rathmell WK, Fahey Catherine C, Hacker Kathryn E, Smith Angela B, Wallen Eric M, Shen H, Laird Peter W, Shuch B, Muzny D, Buhay C, Wang M, Chao H, Dahdouli M, Xi L, Kakkar N, Reid Jeffrey G, Downs B, Drummond J, Morton D, Doddapaneni H, Lewis L, English A, Meng Q, Kovar C, Wang Q, Hale W, Hawes A, Kalra D, Walker K, Murray Bradley A, Sougnez C, Saksena G, Carter Scott L, Schumacher Steven E, Tabak B, Zack Travis I, Getz G, Beroukhim R, Gabriel Stacey B, Meyerson M, Ally A, Balasundaram M, Birol I, Brooks D, Butterfield Yaron SN, Chuah E, Clarke A, Dhalla N, Guin R, Holt Robert A, Kasaian K, Lee D, Li Haiyan I, Lim E, Ma Y, Mayo M, Moore Richard A, Mungall Andrew J, Schein Jacqueline E, Sipahimalani P, Tam A, Thiessen N, Wong T, Jones Steven JM, Marra Marco A, Auman JT, Tan D, Meng S, Jones Corbin D, Hoadley Katherine A, Mieczkowski Piotr A, Mose Lisle E, Jefferys Stuart R, Roach J, Veluvolu U, Wilkerson Matthew D, Waring S, Buda E, Wu J, Bodenheimer T, Hoyle Alan P, Simons Janae V, Soloway Mathew G, Balu S, Parker Joel S, Hayes DN, Perou Charles M, Weisenberger Daniel J, Bootwalla Moiz S, Triche T Jr, Lai Phillip H, Van Den Berg DJ, Baylin Stephen B, Chen F, Coarfa C, Noble Michael S, DiCara D, Zhang H, Cho J, Heiman David I, Gehlenborg N, Voet D, Lin P, Frazer S, Stojanov P, Liu Y, Zou L, Kim J, Lawrence Michael S, Chin L, Yang L, Seth S, Bristow Christopher A, Protopopov A, Song X, Zhang J, Pantazi A, Hadjipanayis A, Lee E, Luquette Lovelace J, Lee S, Parfenov M, Santoso N, Seidman J, Xu Andrew W, Kucherlapati R, Park Peter J, Kang H, Lee J, Roberts Steven A, Klimczak Leszek J, Fargo D, Lang M, Choi Y-L, Kim Sang C, Lee J-K, Park W-Y, Wang W, Fan Y, Ahn J, Akbani R, Weinstein John N, Haussler D, Ma S, Radenbaugh A, Zhul J, Biehl M, Lichtenberg Tara M, Zmuda E, Black Aaron D, Hanf B, Ramirez Nilsa C, Wise L, Bowen J, Leraas Kristen M, Hall Tracy M, Gastier-Foster Julie M, Kaelin William G, Thorne L, Boice L, Huang M, Vocke C, Peterson J, Worrell R, Merino M, Czerniak Bogdan A, Aldape Kenneth D, Wood Christopher G, Spellman Paul T, Atkins Michael B, Cheville J, Thompson RH, Jensen Mark A, Pihl T, Wan Y, Ayala B, Baboud J, Velaga S, Walton J, Liu J, Chudamani S, Wu Y, Sheth M, Mills Shaw Kenna R, Demchok John A, Davidsen T, Yang L, Wang Z, Tarnuzzer Roy W, Zhang J, Eley G, Felau I, Zenklusen Jean C, Hutter Carolyn M, Guyer Mark S, Ozenberger Bradley A, Sofia Heidi J, Chin L, Meyerson M, Kucherlapati R, Park W-Y, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ (2014) The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26(3):319–330. https://doi.org/10.1016/j.ccr.2014.07.014
doi: 10.1016/j.ccr.2014.07.014
pubmed: 25155756
pmcid: 4160352
Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7):1663–1671. https://doi.org/10.1002/cncr.11234
doi: 10.1002/cncr.11234
pubmed: 12655523
Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20(23):4559–4566. https://doi.org/10.1200/jco.2002.05.111
doi: 10.1200/jco.2002.05.111
pubmed: 12454113
Meskawi M, Sun M, Ismail S, Bianchi M, Hansen J, Tian Z, Hanna N, Trinh QD, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI (2013) Fuhrman grade [corrected] has no added value in prediction of mortality after partial or [corrected] radical nephrectomy for chromophobe renal cell carcinoma patients. Mod Pathol 26(8):1144–1149. https://doi.org/10.1038/modpathol.2012.230
doi: 10.1038/modpathol.2012.230
pubmed: 23370773
Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR (2013) The international society of urological pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37(10):1490–1504. https://doi.org/10.1097/PAS.0b013e318299f0fb
doi: 10.1097/PAS.0b013e318299f0fb
pubmed: 24025520
Siddiqui SA, Frank I, Cheville JC, Lohse CM, Leibovich BC, Blute ML (2009) Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int 104(6):778–785. https://doi.org/10.1111/j.1464-410X.2009.08499.x
doi: 10.1111/j.1464-410X.2009.08499.x
pubmed: 19338559
Leibovich BC, Lohse CM, Cheville JC, Zaid HB, Boorjian SA, Frank I, Thompson RH, Parker WP (2018) Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 73(5):772–780. https://doi.org/10.1016/j.eururo.2018.01.005
doi: 10.1016/j.eururo.2018.01.005
pubmed: 29398265
Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V (2012) Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int 110(1):76–83. https://doi.org/10.1111/j.1464-410X.2011.10690.x
doi: 10.1111/j.1464-410X.2011.10690.x
pubmed: 22044519
Frees S, Kamal MM, Knoechlein L, Bell R, Ziesel C, Neisius A, Thomas C, Brenner W, Jager W, Thuroff JW, Roos FC (2016) Differences in overall and cancer-specific survival of patients presenting with chromophobe versus clear cell renal cell carcinoma: a propensity score matched analysis. Urology 98:81–87. https://doi.org/10.1016/j.urology.2016.05.048
doi: 10.1016/j.urology.2016.05.048
pubmed: 27262395
Daugherty M, Sedaghatpour D, Shapiro O, Vourganti S, Kutikov A, Bratslavsky G (2017) The metastatic potential of renal tumors: influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols. Urol Oncol 35(4):153.e115-153.e120. https://doi.org/10.1016/j.urolonc.2016.11.009
doi: 10.1016/j.urolonc.2016.11.009
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandez-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A (2019) Intensive imaging-based follow-up of surgically treated localised renal cell carcinoma does not improve post-recurrence survival: results from a european multicentre database (RECUR). Eur Urol 75(2):261–264. https://doi.org/10.1016/j.eururo.2018.10.007
doi: 10.1016/j.eururo.2018.10.007
pubmed: 30318330
Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours UICC International Union Against Cancer, 7th edn. Wiley-Blackwell, Hoboken
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2011) AJCC cancer staging manual, 7th edn. Springer, Berlin
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandez-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A (2019) Long-term outcomes of follow-up for initially localised clear cell renal cell carcinoma: RECUR database analysis. Eur Urol Focus 5(5):857–866. https://doi.org/10.1016/j.euf.2018.02.010
doi: 10.1016/j.euf.2018.02.010
pubmed: 29525381
Casuscelli J, Becerra MF, Seier K, Manley BJ, Benfante N, Redzematovic A, Stief CG, Hsieh JJ, Tickoo SK, Reuter VE, Coleman JA, Russo P, Ostrovnaya I, Hakimi AA (2019) Chromophobe renal cell carcinoma: results from a large single-institution series. Clin Genitourin Cancer 17(5):373-379.e374. https://doi.org/10.1016/j.clgc.2019.06.011
doi: 10.1016/j.clgc.2019.06.011
pubmed: 31326335
pmcid: 6790280
Jiang HM, Wei JH, Zhang ZL, Fang Y, Zhou BF, Chen ZH, Lu J, Liao B, Zhou FJ, Luo JH, Chen W (2016) Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis. Int Urol Nephrol 48(2):191–199. https://doi.org/10.1007/s11255-015-1161-3
doi: 10.1007/s11255-015-1161-3
pubmed: 26589610